Bioventus Inc. (BVS)

From the record

Bioventus Inc.'s filings since 2017 show 3 warning events: a late-report notice (Form NT 10-K or NT 10-Q, 3 times, the latest 2023-05-11) (its current reports).

From the record

Bioventus Inc.'s 7 filed years say what it did: revenue went from $340 million in fiscal 2019 to $568 million in fiscal 2025, up 8.9% a year; it rose in 4 of 6 years; the deepest fall was 6% from fiscal 2019 to fiscal 2020; net income was positive in 4 of 7 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Bioventus Inc.'s diluted share count grew about 3.9% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 3 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Bioventus Inc. earned about 12 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 57 cents per dollar of everything the company owns. Leverage: it owed about 73 cents per dollar of assets, and net share issuance: its share count grew 6.8% over the year (the filed statements).

From the record

Bioventus Inc.'s standing among 109 graded names in its industry family: revenue of $568 million in fiscal 2025 ranks in the top 26% by size; a net margin of 4% ranks in the top 28%; revenue growth of 3.5% a year over the last 3 filed years ranks in the bottom 30% (its annual reports).

From the record

Bioventus Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Claypoole, Robert E (President and CEO, as filed), filing under that title since 2024-01-12, 2.8 years (bottom 39% of its family); the 15 officers and directors filing in the last fifteen months have been on the record a median of 5.8 years (top 48%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 15 people in charge now (top 12%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Bioventus Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $51 million against debt of $279 million leaves -33.3% of its assets as net cash, bottom 6% of its family; cash from operations less capital spending is 12.7% of revenue (top 19%); a gross margin of 68.3% (top 35%); research spending of 2.1% of revenue (bottom 9%) (its annual report).

From the record

Bioventus Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 3.5% a year over the last three filed years against 8.9% over all 7, slowing (bottom 34% of its family); the newest year grew -0.9% (bottom 21%); research spending grew -20.2% a year (bottom 6%); capital spending grew 20.1% a year (top 26%) (its annual reports). Bioventus Inc. reported 2 lines of business in fiscal 2025: US at $502 million, International at $66 million. 0 of 2 grew in the latest filed year, and the largest line is 88% of revenue (its annual report).

From the record

Bioventus Inc.'s newest year against its own record: revenue of $568 million in fiscal 2025 came in 6.3% below the $607 million its prior three years' pace pointed to (bottom 40% of its family); net income of $23 million against a prior three-year average of $117 million (top 13%); a net margin of 4% against -22.6% before (top 29%) (its annual reports).